肿瘤耐药基因检测的临床应用  

Clinical Application of Drug-resistance Gene Malignant Tumor

作　　者：雷光瑜[1] 许建琼[1] 刘志军[1] 

机构地区：[1]四川省绵阳市第三人民医院,四川绵阳621000

出　　处：《四川肿瘤防治》2007年第3期160-162,共3页Sichuan Journal of Cancer Control

摘　　要：目的：探讨耐药基因产物胸苷酸合成酶（TS）、谷胱甘肽-S-转移酶P i（GST-P i）、拓普异构酶Ⅱa（TopoⅡ）和增殖细胞抗原K i-67在恶性肿瘤组织中的表达及其临床应用。方法：应用免疫组化技术检测90例恶性肿瘤组织中TS、GST-P i和TopoⅡ和K i-67的表达,根据其结果和耐药机制指导临床化疗和药物适配分析。结果：总的阳性表达率TS48%,GST-P i69%,K i-67和TopoⅡ均为99%;而同一耐药基因产物在不同类型肿瘤中的阳性表达率TS为41%~100%,GST-P i为24%~91%,K i-67和TopoⅡ均为92%~100%。阳性细胞比例半定量TS是10%~60%,GST-P i和TopoⅡ均为10%~80%,K i-67是10%~90%。在药物适配分析中对两类药物敏感细胞比例之和≥110%的病例可达到99%。结论：组合检测TS、GST-P i、TopoⅡ和K i-67,基本上满足各类恶性肿瘤耐药基因检测的需要;以定性和百分比半定量结果指导临床化疗有一定参考价值。Objective： To study the protein expression and its clinical application of drug-resistance gene Thymidylate Synthase（TS）, Glutatione S-Transferase Pi（ GST-Pi）, Topoisomerase Ⅱ a（ Tope Ⅱ ） and growth cell antigen Ki-67 in malignant tumor tissue. Methods： TS, GST-Pi,Tope Ⅱ and Ki-67 protein expression in 90 cases of malignant tumor were detected by immunohistochemical assay. Acoording to the drug-resistance gene mechanism those results were used to directing individuality clinical chemotherapy and the pharmaceutical fitting analysis between the results and the drugs. Results： The total positive rate of TS was 48%, GST-Pi was 69%, both Ki-67 and Tope Ⅱ was 99% ; and positive rate of identical drug-resistance gene in different type tumors was that TS was 41% -100%, GST-Pi was 24%-91%, both Ki-67 and Tope Ⅱ was 92%-100% ; in half quantity of positive expression, TS was 10%-60%, both GST-Pi and Tope Ⅱ was 10%-80%, Ki-67 was 10%-90%. In the pharmaceutical fitting analysis, there were 99% cases whose summation of percent rade of sensitive cell 2 kinds of to drugs was more than 110%. Conclusion： Deatecting of TS, GST-Pi, Tope Ⅱ, and Ki-67 can satisfy the needs of drug-resistance gene detection in patients with all kinds of malignant tumor basically. A good individuality pharmaceutical fitting between the results of both quality and percent rate quantity and the drugs by using the results.

关 键 词：耐药基因 临床应用 半定量 药物适配 

分 类 号：R730.5[医药卫生—肿瘤]